Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Sanofi - American Depositary Shares (NQ: SNY )

54.50 +0.51 (+0.94%)
Streaming Delayed Price Updated: 4:00 PM EST, Feb 14, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,806,439
Open 54.77
Bid (Size) 54.00 (3)
Ask (Size) 55.00 (9)
Prev. Close 53.99
Today's Range 54.05 - 54.77
52wk Range 45.22 - 58.97
Shares Outstanding 1,250,690,553
Dividend Yield 3.74%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
How Is The Market Feeling About Sanofi?
Via Benzinga
Sanofi/Johnson & Johnson Partnered Vaccine Against Bacterial Sepsis Flunks Late-Stage Study
Sanofi and J&J halted a phase 3 E. coli vaccine trial due to insufficient efficacy. Sanofi's Q4 2024 IFRS EPS dropped by €0.15 following a $250M charge. 
Via Benzinga

Performance

YTD
+13.09%
+13.09%
1 Month
+7.41%
+7.41%
3 Month
+12.35%
+12.35%
6 Month
-0.04%
-0.04%
1 Year
+18.02%
+18.02%

More News

Read More
Arcutis Soared In 2024, Blazing Trails In Dermatology. Why Its CEO Eyes Bigger Gains.
Via Investor's Business Daily
Exposures Product Safety
Why Regeneron Pharmaceuticals Stock Topped the Market on Tuesday
Via The Motley Fool
Sanofi Buys Back ~$3 Billion In Shares From L'Oréal: Details
Via Benzinga
Sanofi (SNY) Q4 2024 Earnings Call Transcript
Via The Motley Fool
Topics Earnings
Exposures Financial
How Is The Market Feeling About Sanofi?
Via Benzinga
Price Over Earnings Overview: Sanofi
Via Benzinga
How Is The Market Feeling About Sanofi?
Via Benzinga
Earnings Scheduled For January 30, 2025
Via Benzinga
Teva's Duvakitug Set To Shake Up IBD Treatment, Analyst Highlights Competitive Data
Via Benzinga
Moderna, Pfizer Surge Amid CDC-WHO Split And Bird Flu; RFK Jr. Nomination Looms — A Recipe For The Perfect Storm?
Via Benzinga
Topics Government
Exposures Political
Sanofi Genzyme Facility Draws FDA Criticism Over Alleged Quality Lapses
Via Benzinga
Exposures Product Safety
AI Drug Discovery Startups: Analysis Of Exscientia’s Acquisition By Recursion
Via Talk Markets
Topics Artificial Intelligence Stocks / Equities
Exposures Artificial Intelligence
Why Verona Pharma, A Triple-Digit Gainer In 2024, Surged Another 22% This Week
Via Investor's Business Daily
A Look Into Sanofi Inc's Price Over Earnings
Via Benzinga
Sanofi's Blood Cancer Drug's New Subcutaneous Formulation Hits Primary Goal In Late-Stage In Multiple Myeloma
Via Benzinga
Bird Flu Sparks Vaccine Stock Surge: ETFs To Watch As H5N1 Outbreak Intensifies
Via Benzinga
Topics ETFs
Teva Pharmaceutical, Li Auto, And Darden Restaurants Are Among Top Large Cap Gainers Last Week (December 16-20): Are The Others In Your Portfolio?
Via Benzinga
Why Cytokinetics Stock Was a Nearly 5% Winner Today
Via The Motley Fool
In a market where value is scarce, NASDAQ:SNY offers a refreshing opportunity with its solid fundamentals.
Via Chartmill
Teva Pharmaceutical Releases Impressive Phase 2 Candidate Data For Gastro-Related Diseases
Via Benzinga
RCI Hospitality, Quantum Computing, Teva Pharmaceutical, Tesla And Other Big Stocks Moving Higher On Monday
Via Benzinga
Teva Catapults 20%, Nearing A Five-Year High, After Scoring A Win With Sanofi-Tied Drug
Via Investor's Business Daily
Why Are Teva And Sanofi Stocks Trading Higher On Tuesday?
Via Benzinga
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.